For the Inventor, By the Inventor

Enter assignee name

Lyngby, Denmark

Symphogen A/s

USPTO Granted Patents = 24

% Expired Patents = 58.3

CIPO Patents = 4

EPO Patents = 14

Trademarks = 1

Forward Citations = 339

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Mikkel Wandahl Pedersen (13 out of 18 patents)

Klaus Koefoed (9 out of 15 patents)

Michael Kragh (9 out of 14 patents)

4. Johan Lantto (7 out of 9 patents)

5. Helle Jane Jacobsen (7 out of 7 patents)

6. Thomas Bouquin (5 out of 8 patents)

7. Peter Sejer Andersen (5 out of 11 patents)

8. Gunther Roland Galler (4 out of 7 patents)

9. Per-Johan Meijer (4 out of 4 patents)

10. Allan Jensen (4 out of 4 patents)

11. Lars Soegaard Nielsen (4 out of 5 patents)

12. Torben Gjetting (3 out of 8 patents)

13. Michael Monrad Grandal (3 out of 8 patents)

14. Monika Gad (3 out of 6 patents)

15. Ivan David Horak (3 out of 8 patents)

24 patents: Sort by Forward Citations

1. 11390676 - Anti-LAG-3 antibodies and compositions (2022-07-19),

2. 11390674 - Anti-TIM-3 antibodies and compositions (2022-07-19),

3. 11359018 - Anti-PD-1 antibodies and compositions (2022-06-14),

4. 11034765 - Anti-PD-1 antibodies and compositions (2021-06-15),

5. 10450376 - Anti-MET antibodies and compositions (2019-10-22),

6. 10221246 - Pan-HER antibody composition (2019-03-05),

7. 10058610 - Methods for treating cancer by administering humanized pan-HER antibody compositions (2018-08-28),

8. 9527913 - Humanized pan-HER antibody compositions (2016-12-27),

9. 9217039 - Anti-HER3 antibodies and compositions (2015-12-22),

10. 9163232 - Method for manufacturing recombinant polyclonal proteins (2015-10-20),

11. 9155802 - Pan-HER antibody composition (2015-10-13),

12. 9029091 - Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line (2015-05-12),

13. 8663640 - Methods using recombinant anti-epidermal growth factor receptor antibody compositions (2014-03-04),

14. 8609095 - Anti-HER2 antibodies and compositions (2013-12-17),

15. 8414896 - Recombinant anti-epidermal growth factor receptor antibody compositions (2013-04-09),

Symphogen A/S is a biopharmaceutical company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. They utilize their proprietary Symplex® discovery platform to develop antibody mixtures that target multiple cancer pathways, increasing treatment efficacy. Symphogen's goal is to advance innovative and personalized cancer therapies to improve patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

24 Patents

#5 in Lyngby

#121 in Denmark

#26,595 in the World

Lyngby, Denmark

Symphogen A/s

Forward Citations = 339

53 inventors:

Mikkel Wandahl Pedersen (13 out of 18 patents)

Klaus Koefoed (9 out of 15 patents)

Michael Kragh (9 out of 14 patents)

4. Johan Lantto (7 out of 9 patents)

5. Helle Jane Jacobsen (7 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…